Thérapies de Conversion
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.
Zhang X, Cai H, Peng W, Wang H, Wu J, Zhu X, Guo W, Xie F, Zhang Y, Wang M, Yu Y, Zhou Y, Li C, Shen J, Liu C, Yang Y, Jiang X, Li Q, Chen W, Shi Y, Lu W, Sun X, Feng X, Yan M, Cheng S, Wen T
Signal Transduct Target Ther
.
2026;11 (1) :37
Résumé
Conversion therapy remains an uncommon strategy for managing unresectable hepatocellular carcinoma (uHCC) due to limited evidence supporting its efficacy. To address this gap, we initiated a prospective phase 2 multicenter trial (NCT04997850) comparing the LEN-TAP regimen, combining lenvatinib, transarterial chemoembolization (TACE), and PD-1 inhibitors, against TACE alone in uHCC patients. The study's primary outcome was salvage liver resection (SLR) rate; secondary measures included objective response rate (ORR), overall survival (OS), event-free survival (EFS), recurrence-free survival (RFS), and safety profile. From October 2020 to November 2021, 142 eligible participants were assigned to LEN-TAP (n = 71) or TACE monotherapy (n = 71). At a median follow-up of 24.2 months, the LEN-TAP cohort exhibited a significantly higher SLR rate (59.2% vs. 18.3%, P
